Oncology
Refine Search
Pharmaceutical
US biopharma company Galmed Pharmaceuticals has entered into a research collaboration with Virginia Commonwealth University to investigate its lead candidate Aramchol (arachidyl amido cholanoic acid) as a potential solution to drug resistance in gastrointestinal cancers. 17 April 2025
Biotechnology
BigHat Biosciences, a Californian biotech with a machine learning (ML)-guided antibody discovery and development platform, has announced a strategic collaboration with US pharma major Eli Lilly. 17 April 2025
Biotechnology
US cancer drug developer Werewolf Therapeutics today announced the appointment of Steven Bloom as chief business officer (CBOP. 17 April 2025
Pharmaceutical
French drugmaker Ipsen today presented sales for the first quarter of 2025. The company did not release any earnings figures. 16 April 2025
Pharmaceutical
Shares in Johnson & Johnson were 1% lower in the early stages of Tuesday’s trading after the US health conglomerate presented its first-quarter 2025 financial results. 15 April 2025
Biotechnology
Spanish biotech Reveal Genomics has formed a strategic partnership with oncology firm Ona Therapeutics to support the clinical development of ONA-255, a novel antibody-drug conjugate designed to target therapy-resistant tumor cells in advanced solid cancers. 15 April 2025
Biosimilars
Shares of California-based Coherus BioSciences (Nasdaq: CHRS) rose more than 5% to $0.88 in pre-market activity today as it completed a transformative transaction. 14 April 2025
Biotechnology
The European Commission has approved Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified who are ineligible for autologous stem cell transplant (ASCT), Swiss pharma giant Roche announced this morning. 14 April 2025
Pharmaceutical
Deal-making news last week included US drug developer KalVista Pharma signing a licensing agreement with Kaken Pharma to market its investigational hereditary angioedema (HAE) drug sebetralstat in Japan. US biotech firm Cartesian Therapeutics released positive Phase IIb data on its Descartes-08 in myasthenia gravis. The US Appeal Court gave a favorable ruling on Indian drugmaker Sun pharmaceuticals’ alopecia drug Leqselvi. Also of note, the US Food and Drug Administration (FDA) last week approved Bristol Meyers Squibb’s checkpoint therapy Opdivo plus Yervoy. 13 April 2025
Biotechnology
Johnson & Johnson has announced new data from an analysis modelling long-term progression free survival (PFS) in transplant eligible (TE) and transplant ineligible (TIE) newly diagnosed multiple myeloma (NDMM) patients given Darzalex (daratumumab)-subcutaneous (SC) therapy alongside bortezomib, lenalidomide and dexamethasone (VRd). 11 April 2025
Biotechnology
US biotech giant Amgen today announced a significant breakthrough with its global Phase III DeLLphi-304 clinical trial evaluating Imdelltra (tarlatamab-dlle). 11 April 2025
Pharmaceutical
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s Truqap (capivasertib) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread. 11 April 2025
Biotechnology
US biotech Atossa Therapeutics has entered into a research collaboration with China-backed Nona Biosciences, aiming to identify next-generation antibody therapies for breast cancer using Nona’s proprietary platform technology. 10 April 2025
Pharmaceutical
The UK’s National Institute of Health and Care Excellence (NICE) has recommended erdafitinib, trade name Balversa and manufactured by Johnson & Johnson, for some adult patients in England. 10 April 2025
Biotechnology
Solu Therapeutics, a US biotech developing therapies to eliminate disease-driving cells in cancer, immunology and other therapeutic areas, has announced the successful completion of a $41 million Series A financing. 10 April 2025
Biotechnology
Privately-held Finland-based Valo Therapeutics (ValoTx), an immunotherapy company developing novel, adaptable treatments for cancer, today announced the appointment of Marcella Origgi as its chief executive (CEO) of its Helsinki headquarters and Naples, Italy, subsidiary. 9 April 2025
Biotechnology
Myricx Bio, a UK biotech focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), is expanding its team. 8 April 2025
Biotechnology
Datroway (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting. 8 April 2025
Biotechnology
Following hot on the heels of Monday’s European Commission EC approval of an indication extension for Johnson & Johnson’s Darzalex (daratumumab) for the treatment of adult patients with newly diagnosed multiple myeloma, comes a second EC approval today – this time in lung cancer. 8 April 2025
Biotechnology
China-based biotech DualityBio has named Hua Mu as its global chief medical officer, as the company prepares to ramp up its international clinical development efforts and advance toward key capital market milestones. 7 April 2025
Pharmaceutical
Norwegian bladder cancer specialist Photocure has appointed Jane Healy as vice president and general manager EMEA. 26 March 2025
Biotechnology
US clinical-stage biotech Syncromune today announced the appointment of Zhihong Li as chief regulatory affairs officer. 25 March 2025
Biotechnology
The emergence of degrader-antibody conjugates (DACs) has attracted much attention, with a potential to transform the precision medicine landscape, notes data and analytics company GlobalData. 25 March 2025
Biotechnology
New study results have shown the role of AstraZeneca’s Tagrisso (osimertinib) as monotherapy and as the backbone for novel combinations across stages and settings of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). 25 March 2025
Pharmaceutical
Despite data showing that cancer is on track to become the leading cause of death in the European Union (EU) by 2035, encouraging signs are emerging. 25 March 2025
Biotechnology
Danish biotech on Saturday revealed that US pharma major (AbbVie has filed a complaint in the US District Court for the Western District of Washington, naming Genmab, ProfoundBio and former AbbVie employees as defendants. 22 March 2025
Pharmaceutical
Dizal Pharmaceutical will present new research findings on two of its innovative drugs - sunvozertinib and golidacitinib - at the 2025 European Lung Cancer Congress (ELCC) The studies focus on addressing resistance in non-small cell lung cancer (NSCLC) treatments. 21 March 2025
Biotechnology
Chinese biotech Akeso has reported encouraging early data from a Phase III trial of its bispecific antibody cadonilimab (AK104) in combination with chemoradiotherapy for patients with locally advanced cervical cancer. 21 March 2025
Pharmaceutical
The New Drug Application (NDA) for Tazverik (tazemetostat) has been granted conditional approval in China for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) with EZH2 mutation who have received at least two prior systemic therapies, said the drug’s developer, Chinese biopharma Hutchmed. 21 March 2025
Pharmaceutical
US healthcare giant Johnson & Johnson has announced manufacturing, research and development and technology investments of more than $55 billion in the USA over the next four years. 21 March 2025
Biotechnology
Monte Rosa Therapeutics, a US biotech developing novel molecular glue degrader (MGD)-based medicines, closed Thursday’s trading more than 5% higher. 21 March 2025
Biotechnology
Akari Therapeutics, a US biotech developing next-generation bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, has announced the appointment of Abizer Gaslightwala as president and chief executive. 20 March 2025
Pharmaceutical
Today, Cambridge, USA-based clinical-stage oncology company Immuneering announced the appointment of Dr Igor Matushansky as chief medical officer (CMO). 20 March 2025
Biotechnology
Elevation Oncology has decided to discontinue development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC) which was being developed for the treatment of advanced, unresectable or metastatic gastric and gastroesophageal junction (GEJ) cancers. 20 March 2025
Biotechnology
Chugai Pharmaceutical has launched Lunsumio (mosunetuzumab) in Japan for patients with relapsed or refractory follicular lymphoma who have undergone at least two prior standard therapies. 20 March 2025
Biotechnology
Chimeric antigen receptor T-cell (CAR-T) therapeutics have emerged as a dominating cancer treatment within cell and gene therapies (CGT). 20 March 2025
Biotechnology
Japanese drugmaker Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the treatment of adults with hormone receptor (HR) positive, HER2 negative, unresectable or recurrent breast cancer after prior chemotherapy. 20 March 2025
Pharmaceutical
Whitehawk Therapeutics , formerly Aadi Bioscience, has officially rebranded to reflect its transformation into a pre-clinical-stage biotech focused on antibody-drug conjugates (ADCs). 19 March 2025
Pharmaceutical
French independent pharma firm Servier and USA-based Black Diamond Therapeutics, a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class targeted therapy for solid tumors 19 March 2025
Biotechnology
Chinese pair Hutchmed and Innovent Biologics have announced that the FRUSICA-2 Phase II/III trial of fruquintinib and sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (RCC) in China has met its primary endpoint. 19 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze